GSK plc Reports Transaction in Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Aug 13, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Aug 13, 2025 |
| Risk Level | low |
| Pages | 8 |
| Reading Time | 10 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, disclosure, 6-K
Related Tickers: GSK
TL;DR
GSK bought back some of its own stock, filing a 6-K on Aug 13, 2025.
AI Summary
GSK plc announced a transaction in its own shares on August 13, 2025. The filing, a Form 6-K, indicates the company is acting through its corporate broker for this transaction. Further details on the specific nature and value of the share transaction were not provided in this initial report.
Why It Matters
This filing signals GSK's activity in managing its own stock, which can impact share count and potentially influence stock price. Investors will look for more details to understand the implications.
Risk Assessment
Risk Level: low — This is a routine disclosure of a company's own share transactions, which is common and generally low risk.
Key Players & Entities
- GSK plc (company) — Registrant
- August 2025 (date) — Reporting period
- 001-15170 (other) — Commission File Number
FAQ
What type of transaction did GSK plc report?
GSK plc reported a 'Transaction in own shares'.
What form was filed with the SEC?
GSK plc filed a Form 6-K.
For what period is this report?
The report is for the month of August 2025.
Who is acting on behalf of GSK plc for this transaction?
The filing states that GSK plc is acting through its corporate broker.
What is GSK plc's principal executive office address?
GSK plc's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Filing Stats: 2,513 words · 10 min read · ~8 pages · Grade level 2.2 · Accepted 2025-08-13 06:03:14
Filing Documents
- a0655v.htm (6-K) — 4252KB
- 0001654954-25-009467.txt ( ) — 4253KB
From the Filing
IN OWN SHARES a0655v UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of August 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .                                       Transaction in own shares   GSK plc (the " Company ") announces today   acting through its corporate stockbroker, Merrill Lynch International (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.     Date of purchase: 12 August 2025 Aggregate number of ordinary shares of  31¼  pence each purchased: 495,245 Lowest price paid per share (GBp): 1,395.50p Highest price paid per share (GBp): 1,405.00p Volume-weighted average price paid per share (GBp): 1,401.27p     The purchased shares will be held as Treasury shares.   Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 22,898,238 ordinary shares.   Following the above purchase, the Company will hold 241,032,621 ordinary shares in treasury and have 4,074,358,625 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,074,358,625. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is   5.92 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.       Schedule of Purchases Shares purchased:      GSK plc (ISIN: GB00BN7SWP63)   Date of purchases:     12 August 2025 Investment firm:        Merrill Lynch International       Aggregated information per trading venue:   Venue Number of ordinary shares purchased Highest price paid (per ordinary share) (GBp) Lowest price paid (per ordinary share) (GBp) Volume weighted average price paid (per ordinary share) (GBp) London Stock Exchange (XLON) 495,245 1,405.00p 1,395.50p 1,401.27p CBOE (CHIX) 0 - - - CBOE (BATE) 0 - - -     Individual transactions:   Number ofShares Price per Share (GBp) Tradingvenue Date oftransaction Time oftransaction Transaction reference number 12 1,401.00  XLON 12-Aug-2025 08:00:30 0XL06140000000005MJ6CL 13 1,401.00  XLON 12-Aug-2025 08:00:30 0XL06140000000005MJ6CN 31 1,401.00  XLON 12-Aug-2025 08:00:30 0XL06140000000005MJ6CM 2 1,403.00  XLON 12-Aug-2025 08:02:03 0XL06A00000000005MJ6KR 11 1,403.50  XLON 12-Aug-2025 08:02:03 0XL06D00000000005MJ6I6 11 1,404.00  XLON 12-Aug-2025 08:02:03 0XL06A00000000005MJ6KQ 12 1,403.50  XLON 12-Aug-2025 08:02:03 0XL06100000000005MJ6DF 12 1,403.50  XLON 12-Aug-2025 08:02:03 0XL06110000000005MJ6JT 12 1,403.50  XLON 12-Aug-2025 08:02:03 0XL06700000000005MJ6LH 12 1,404.50  XLON 12-Aug-2025 08:02:03 0XL06110000000005MJ6JR 12 1,404.50  XLON 12-Aug-2025 08:02:03 0XL06A00000000005MJ6KO 13 1,403.50  XLON 12-Aug-2025 08:02:03 0XL06D00000000005MJ6I7 13 1,404.00  XLON 12-Aug-2025 08:02:03 0XL06100000000005MJ6DE 13 1,404.00  XLON 12-Aug-2025 08:02:03 0XL06170000000005MJ6JI 32 1,404.50  XLON 12-Aug-2025 08:02:03 0X